TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05447624

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of genicular nerves
Description: The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of genicular nerves
Description: The RF cannula will be placed near the nerve with an in-plane technique from proximal to distal. Sensory stimulation will be performed at 50 Hz to ensure localization. The sensory threshold should be less than 0.6 V. To prevent ablation of the motor nerves, when the nerve is stimulated with 2.0 V at 2 Hz, it will be seen that there is no fasciculation in the relevant region of the lower extremity. Before starting the ablation procedure, 2 mL of 1% lidocaine solution will be injected around the nerve, after vascularity control, in order to reduce the pain and the risk of neuritis during the procedure. Then the temperature will be adjusted to 80° degrees and applied for 90 seconds and the process will be terminated.
Study: NCT04710043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT152
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT152
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT152
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT152
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT152
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT153
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT153
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT153
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT153
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT153
Description: intravenous
Study: NCT06159374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and environmental conditions
Description: Participants will perform interval training for 4 weeks in a variety of environmental conditions. There will be a measurement of aerobic and anaerobic capacity before and after the training. Before and after the first and last workout, blood will be drawn for biochemical analysis.
Study: NCT06010290

Intervention type: DRUG
Intervention: 18F-SMBT-1
Description: Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.

Intervention type: DRUG
Intervention: 18F-SMBT-1
Description: Each participant receives intravenous injection of 18F-SMBT-1, and undergo PET/CT imaging within the special time. 18F-FP-CIT and 18F-FDG PET/CT are used to assess the change of cerebral dopamine transporters and glucose metabolism for auxiliary diagnosis.
Study: NCT05672303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palmar grasp reflex
Description: The reflex can be stimulated by moving an object distally across the palm. In the study, at the beginning of the vaccine administration, the right hand of the infant will be moved distally along the palm with the researcher's index finger, thus providing reflex stimulation.
Study: NCT05985603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT Group
Description: In this group of patients CIMT technique will be used for treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy group
Description: patient will perform movements in semi-reclined and sitting positions with the mirror placed between the two lower extremities.
Study: NCT06342895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nutritional support prescription and delivery monitoring feedback
Description: Real-time availability in an integrated computer interface (Nutrow) of all clinical and biological information related to nutritional support including recommended, prescribed, and delivered calories and proteins and enteral feed delivery transmitted by the Feedim medical device

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual care
Description: Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.
Study: NCT05198193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Message Given
Description: Participants in this arm are not given any intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Message Given
Description: Participants in this arm are not given any intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Message Given - Older Adults
Description: Participants in this arm are given a positively framed message from an older adult's point of view.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Message Given - Older Adults
Description: Participants in this arm are given a negatively framed message from an older adult's point of view.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Message Given - Younger Adults
Description: Participants in this arm are given a positively framed message from an adult child's point of view.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Message Given - Younger Adults
Description: Participants in this arm are given a negatively framed message from an adult child's point of view.
Study: NCT05643417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC、Bevacizumab、Camrelizumab
Description: HAIC: refer to genetic test results，D1 Bevacizumab：7.5mg/Kg, D2, Q3W Camrelizumab：200mg, D2, Q3W
Study: NCT04733911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75 eccentric contractions
Description: An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 5 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 150 eccentric contractions
Description: An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 10 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 300 eccentric contractions
Description: An acute bout of eccentric exercise will be performed on an isokinetic dynamometer, including 20 sets of 15 repetitions, with 30 sec rest intervals,at 60 degrees/sec.
Study: NCT05749601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influence of the metabolic syndrome (MetS) parameters on knee osteoarthritis (KOA) severity, the assesment of the reactive oxygen species and reactive nitrogen species in knee synovial fluid
Description: Highlighting the influence of environment of origin on KOA incidence and corelated impact of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and body mass index (BMI). The analytes from synovial fluid were determined by fluorometric method.
Study: NCT04751461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P0213420, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product
Study: NCT05590637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
Study: NCT05633992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
Study: NCT06400966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training method
Description: Jigsaw Technique
Study: NCT05633992

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Study: NCT05942352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligustrazine by intravenously administration
Description: Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligustrazine by intravenously administration
Description: Ligustrazine hydrochloride was administered intravenously by dissolving 40mg in 250ml saline per day for 15 days
Study: NCT04751461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P0213520, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product
Study: NCT05942352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligustrazine by mouth
Description: 50 mg Ligustrazine tablet by mouth would be maintained for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo by intravenously administration
Description: Intravenous administration of 250ml saline per day for 15 days
Study: NCT04751461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product
Study: NCT05942352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo by mouth
Description: 50 mg placebo tablet by mouth would be maintained for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo by mouth
Description: 50 mg placebo tablet by mouth would be maintained for 1 year
Study: NCT06321978

Intervention type: DEVICE
Intervention: Mepilex Border Flex
Description: Usage of Mepilex Border Flex according to intended use and standard of care.
Study: NCT05730790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual task training (DTT)
Description: For session 1 to 3, the training comprises of 4 cycles of the following: 2 min dual tasking, 2 min rest, 2 min dual tasking, 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min dual tasking, 1.5 min rest, 2.5 min dual tasking, 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min dual tasking, 1 min rest, 3 min dual tasking, 1 min rest. The treadmill speed is maintained at 40%, 50% and 60% of participant's original gait speed at session 1 to 3, 4 to 6, and 7 to 14 respectively.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive single task training (CSTT)
Description: For session 1 to 3, the training comprises of 4 cycles of the following: 2 min VR gaming, 2 min rest, 2 min VR gaming and 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 2.5 min VR gaming, 1.5 min rest, 2.5 min VR gaming and 1.5 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 3 min VR gaming, 1 min rest, 3 min VR gaming and 1 min rest.~There are 10 levels in the VR game. Participant will start at level 1 of VR game at session 1 and can progress to the next level at the subsequent session if game percentage \> 80%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor single task training (MSTT)
Description: For session 1 to 3, the training comprises of 4 cycles of the following: 8 min treadmill walking at 40% of participant's original gait speed followed by 2 min rest. For session 4 to 6, the training comprises of 4 cycles of the following: 8 min treadmill walking at 50% of participant's original gait speed followed by 2 min rest. For session 7 to 14, the training comprises of 4 cycles of the following: 8 min treadmill walking at 60% of the participant's original gait speed followed by 2 min rest.
Study: NCT04751461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P0211220, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product
Study: NCT06201975

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thyme honey
Description: Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey
Description: Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
Study: NCT04751461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: P0211820, a 1.8% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: P0213417, a 2.4% nicotine ENDS product
Study: NCT05489263

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention